Alida Biosciences today announced the launch of its EpiPlex™ Tri-Mod™ Service, enabling simultaneous detection and quantification of three key mRNA modifications—N6-methyladenosine (m6A), inosine, and ...

Alida Biosciences today announced the launch of its EpiPlextm Tri-Modtm Service, enabling simultaneous detection and quantification of three key mRNA modifications?N6-methyladenosine (m6A), inosine, ...

Moderna (MRNA) closed at $54.26 in the latest trading session, marking a +2.69% move from the prior day. This change outpaced the S&P 500's 0.8% gain on the day. Meanwhile, the Dow lost 0.15%, and the ...

The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indications; First-in-class METTL3 inhibitor reprograms malignant progenitor cells by modu ...

STORM Therapeutics raises $56M Series C and doses first patient in Phase 2 sarcoma trial of STC-15, the world’s first RNA ...

A nanodisc platform that offers a clearer view of how key viral proteins interact with antibodies could lead to better HIV ...

Eye.ai, a pioneer in integrated optical interconnects, today announced it has raised $80 million in Series C financing led by Sutter Hill Ventures with participation from existing investors including ...

Storm Therapeutics raises $56M in Series C funding to accelerate cancer therapy development and expand its innovative ...

STORM Therapeutics, a Cambridge-based clinical stage company targeting RNA modifications to reprogram cells and develop novel ...

Since 2007, Jezebel has been the Internet's most treasured source for everything celebrities, sex, and politics...with teeth.

Northwestern Medicine scientists have uncovered an unexpected role for a well-known cancer-related protein, revealing a new layer of genetic regulation that could reshape how certain cancers are ...

Scientists assumed that one specific immune cell subtype was required for mRNA vaccination to activate the immune system. But ...